Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab's Impact on Alzheimer's Disease

Dr. Eric Grigsby

NAPA, Calif., July 19, 2023 (VSNewsNetwork.com) - Neurovations, a prominent medical research and innovation company, proudly announces its collaboration on a groundbreaking study examining the effects of donanemab, a monoclonal antibody, on patients in the early stages of Alzheimer's Disease.

Neurovations began enrolling patients in 2021 ahead of Eli Lilly's recent announcement of positive results from the TRAILBLAZER-ALZ 2 Phase 3 trial. This study demonstrated that donanemab significantly slowed cognitive and functional decline in individuals with early Alzheimer's Disease.

"We are thrilled to be part of this vital research. Alzheimer's Disease affects nearly 1 million people in my home state of California," said Dr. Eric Grigsby. "This is a significant step forward in the fight against Alzheimer's, and we are optimistic about the impact this treatment may have on the members of my community with this condition."

The promising findings from the TRAILBLAZER-ALZ 2 study, a randomized, double-blind, placebo-controlled trial, have led to Lilly's plans for FDA approval and global regulatory submissions. Neurovations' involvement in the study, alongside Dr. Eric Grigsby's expertise, has furthered the understanding of donanemab's potential benefits in the management of Alzheimer's disease.

Source: Neurovations via Newswire